



Post Authorisation Assessments

Quiflor 5 mg Tablets for Cats and Dogs

Vm 01656/4044

16 May 2026	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance. (NI).
17 April 2026	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance. (GB).
08 April 2026	Submission of a Ph. Eur. CEP for an active substance. (NI)
09 March 2026	Submission of a Ph. Eur. CEP for an active substance. (GB)
10 February 2026	Deletion of a manufacturing site for an active substance. (NI).
25 November 2025	One-off alignment of the product information with version 3 of the QRD template.
05 November 2025	Deletion of a manufacturing site for an active substance. (GB).
04 May 2024	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance. (NI) Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex. (NI)
20 March 2024	Change in the name or address or contact details of a qualified person for pharmacovigilance. (GB)
28 February 2023	New certificate of suitability from a new manufacturer.
21 February 2023	Change to comply with an update of the relevant monograph of the Ph. Eur. Change to comply with Ph. Eur. by removing reference to the internal test method and test method number.
17 January 2023	Change to comply with an update of the relevant monograph of the Ph. Eur. Change to comply with Ph. Eur. by removing reference to the internal test method and test method number.
14 July 2022	New certificate of suitability from a new manufacturer.
31 December 2020	Minor changes to an approved test procedure of the finished product. Minor changes to an approved test procedure of the finished product. Addition of a manufacturer responsible for batch release including batch control/testing. Addition of a secondary packaging site of the finished product. Addition of a manufacturing site of the finished product. Addition of secondary packaging site of the finished product.
09 May 2019	Addition of a site where batch control takes place Deletion of manufacturing site for an active substance and packaging site.
17 April 2018	Change in RMS from UK to ES.
14 March 2018	Renewal – UK as RMS

26 October 2017	Change in contact details for local representative.
21 December 2016	Increase in the shelf life of the finished product from 2 years to 3 years.
20 July 2016	Extension of retest period for active substance.
20 May 2015	Change in manufacturing site of the active substance
30 April 2015	Addition of UK local representative information to package leaflet.
30 October 2014	Minor changes to test procedures of the finished product.
05 December 2013	Change in the invented name of the veterinary medicinal product from Marfloxin to Quiflor in DE, NL, BE and UK.
28 November 2013	Addition of a manufacturer responsible for batch release.